Research programme: T-cell recruiting therapeutics - Harpoon Therapeutics

Drug Profile

Research programme: T-cell recruiting therapeutics - Harpoon Therapeutics

Alternative Names: HPN 217; HPN 424; HPN 536

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Cytokine stimulants; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer; Solid tumours

Most Recent Events

  • 19 Apr 2018 Preclinical trials in Solid tumours in USA (Parenteral)
  • 19 Apr 2018 Harpoon Therapeutics plans a phase I trial for HPN 536 in Solid tumours (mesothelin positive)
  • 16 Apr 2018 Harpoon Therapeutics intends to file INDs for HPN 424 and HPN 536 in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top